Search

RG-7795

Mexazolam

[A184910] The use of benzodiazepines in the treatment of anxiety is generally a second line measure.[A184910]

Betamethasone phosphate

[L11994] Betamethasone sodium phosphate was granted FDA approval on 3 March 1965.[L11994]

Collagenase clostridium histolyticum

[L14882] The topical formulation is used for the debridement of necrotic tissue due to burns or chronic ulcers. … [L14912] On July 6, 2020 a combination of injectable bacterial collagenases was approved by the FDA for the treatment of cellulite in adult women.

Tolrestat

While it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval. … Tolrestat (INN) (AY-27773) is an aldose reductase inhibitor which was approved for the control of certain diabetic complications.

Methimazole

in pregnancy due to a perceived lower risk of teratogenic effects. … [A184733] Traditionally, methimazole has been preferentially used over propylthiouracil due to the risk of fulminant hepatotoxicity carried by the latter,[A184757] with propylthiouracil being preferred

AS-8112

AS-8112 is a synthetic compound that acts as a selective antagonist at the dopamine receptor subtypes D2 and D3, and the serotonin receptor 5-HT3. … It has been shown to exert potent antiemetic effects in animal studies and has been investigated for potential medical use.

Efanesoctocog alfa

[L45379] The use of FVIII replacement products is beneficial in patients with hemophilia A; however, their quality of life can be affected due to frequent doses. … [A257464] Efanesoctocog alfa was designed to have an extended half-life, and to surpass the half-life ceiling to which other forms of recombinant FVIII are subjected due to their association with von Willebrand

Mipomersen

Due to this serious risk of liver toxicity, mipomersen sodium is only available to patients under the restricted program called Kynamro Risk Evaluation and Mitigation Strategy program. … Specifically, elevations in the liver enzymes, i.e. transaminases, and in liver fat (hepatic steatosis) have been reported.

Chlorobutanol

Due to the long terminal half-life of 37 days, the use of chlorobutanol as a sedative is limited because of the considerable accumulation which will occur following multiple dosing [A32743]. … Chlorobutanol, or chlorbutol, is an alcohol-based preservative with no surfactant activity [A32746].